Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy in Pulmonary Vascular Disease (PVD)
Launched by UNIVERSITY OF ZURICH · Apr 22, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to understand how exercise performance is affected by two different conditions: exercising in normal air versus exercising while using low-flow oxygen therapy. The study specifically focuses on people who have pulmonary vascular diseases, such as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH). These conditions can make it harder for the lungs to get enough oxygen, especially during physical activity.
To participate in this trial, you must be at least 18 years old and have a diagnosis of PAH or CTEPH. You need to be stable on your current medication for at least two weeks before joining the study. However, if you have very low oxygen levels that require extra oxygen, are pregnant, or have any condition that would make it hard to follow the study's procedures, you won't be eligible. Participants will have the chance to engage in exercises while their oxygen levels and overall performance are monitored. This study is not yet recruiting, but it aims to help improve understanding of how these therapies can support people with pulmonary vascular diseases.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Minimum 18 years of age
- • Written informed consent
- • Patients with diagnosed pulmonary arterial hypertension (PAH), distal chronic thromboembolic pulmonary hypertension (CTEPH)
- • Former desaturation under exercise defined as Spo2-decrease \>3%
- • Treated with a stable drug therapy (with no changes for at least 14 days prior to screening)
- Exclusion Criteria:
- • Severe hypoxemia needing supplemental oxygen therapy defined as partial pressure of O2 (PaO2) \< 6.9 Kilopascal (kPa)
- • Pregnancy
- • Unability or contraindications to undergo the investigated intervention
- • Unability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc
About University Of Zurich
The University of Zurich, a leading institution in research and education, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust framework for conducting high-quality research, the university collaborates with multidisciplinary teams of experts to explore cutting-edge therapeutic approaches and interventions. Its commitment to ethical standards and patient safety ensures that all clinical trials are conducted with the utmost integrity, aiming to contribute valuable insights to the medical community and enhance health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zurich, , Switzerland
Patients applied
Trial Officials
Silvia Ulrich, Prof. Dr.
Principal Investigator
University Hospital Zurich, Department of Pulmonology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported